SCHEMBL3768221

SCHEMBL3768221

Cc1ccc(C(=O)NC2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
F10 P00742 1/20 0.46
RIPK2 O43353 1/20 0.46
HRH3 Q9Y5N1 2/20 0.46
DRD4 P21917 2/20 0.45
POLB P06746 1/20 0.44
SETD2 Q9BYW2 2/20 0.43
ACKR3 P25106 1/20 0.43
NSD2 O96028 1/20 0.43
CYP2C8 P10632 1/20 0.43
DRD2 P14416 1/20 0.43
HTR1B P28222 1/20 0.43
CNR2 P34972 2/20 0.43
LMNA P02545 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779258 0.95 KMT2A (0.51) KMT2AMEN1NPC1RAB9AF10
SCHEMBL3773424 0.89 KMT2A (0.61) KMT2AMEN1NPC1RAB9AHRH3
SCHEMBL3769160 0.87 KMT2A (0.53) KMT2AMEN1NPC1RAB9AF10
SCHEMBL3803764 0.86 DRD4 (0.60) KMT2ADRD4
SCHEMBL3762894 0.85 KMT2A (0.57) KMT2AMEN1DRD4POLBLMNA
SCHEMBL3779305 0.84 KMT2A (0.58) KMT2ANPC1RAB9AF10HRH3
SCHEMBL13006775 0.84 KMT2A (0.79) KMT2AMEN1F10HRH3DRD4
SCHEMBL3760993 0.84 KMT2A (0.58) KMT2AMEN1NPC1RAB9AF10
SCHEMBL3774069 0.84 KMT2A (0.57) KMT2AMEN1NPC1RAB9AF10
SCHEMBL3773768 0.84 KMT2A (0.57) KMT2AF10HRH3POLBACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885MEN1 3270/4885NPC1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.